深化对快感缺失机制与病理生理学的理解:我们准备好转化了吗?
本文概述快感缺失的病理生理学知识,指出其与抑郁症不良病程、治疗反应差及自杀风险增加相关,部分神经异常在成功治疗后持续存在,并在高危未患病儿童中可预测首发抑郁。作者提出需开展适当对照的临床试验、开发更具转化价值的新型临床前模型及纳入神经科学进展的临床量表,强调跨物种多水平整合协作。
要点
- 快感缺失与抑郁症不良病程、心理/药物/神经刺激治疗反应差及自杀风险增加相关。
- 部分快感缺失相关神经异常(如腹侧纹状体对奖赏线索激活减弱及功能连接降低)在成功治疗后持续存在。
- 这些神经异常已在未患病、从未抑郁的父母患抑郁症的儿童中识别,并可前瞻性预测首发抑郁症。
核心结论
- 快感缺失的神经异常可能是预防的有希望靶点,但仍存在重要缺口。
- 作者强调需要整合、协作、跨物种和多水平的方法来应对快感缺失表型。
研究设计与样本
- 本文为概述性综述,作者总结了快感缺失病理生理学的现有知识并强调未来优先事项。
主要发现
- 快感缺失与抑郁症不良病程、心理/药物/神经刺激治疗反应差及自杀风险增加相关。
- 部分快感缺失相关神经异常在成功治疗后持续存在,如腹侧纹状体对奖赏相关线索激活减弱及涉及腹侧纹状体的功能连接降低。
- 这些神经异常已在未患病、从未抑郁的父母患抑郁症的儿童中识别,并可前瞻性预测首发抑郁症。
关键数值与推荐
- 需要适当对照的临床试验,尤其是采用实验治疗学方法探测靶点 engagement 的试验。
- 需要与快感缺失相关的新型临床前模型,具有更强转化价值。
- 需要纳入神经科学进展的临床量表以理解快感缺失。
临床怎么用
- 快感缺失的神经异常可能作为预防的有希望靶点。
- 临床研究应优先开展适当对照的临床试验,采用实验治疗学方法探测靶点 engagement。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Anhedonia-the loss of pleasure or lack of reactivity to pleasurable stimuli-remains a formidable treatment challenge across neuropsychiatric disorders. In major depressive disorder, anhedonia has been linked to poor disease course, worse response to psychological, pharmacological, and neurostimulation treatments, and increased suicide risk. Moreover, although some neural abnormalities linked to anhedonia normalize after successful treatment, several persist-for example, blunted activation of the ventral striatum to reward-related cues and reduced functional connectivity involving the ventral striatum. Critically, some of these abnormalities have also been identified in unaffected, never-depressed children of parents with major depressive disorder and have been found to prospectively predict the first onset of major depression. Thus, neural abnormalities linked to anhedonia may be promising targets for prevention. Despite increased appreciation of the clinical importance of anhedonia and its underlying neural mechanisms, important gaps remain. In this overview, the author first summarizes the extant knowledge about the pathophysiology of anhedonia, which may provide a road map toward novel treatment and prevention strategies, and then highlights several priorities to facilitate clinically meaningful breakthroughs. These include a need for 1) appropriately controlled clinical trials, especially those embracing an experimental therapeutics approach to probe target engagement; 2) novel preclinical models relevant to anhedonia, with stronger translational value; and 3) clinical scales that incorporate neuroscientific advances in our understanding of anhedonia. The author concludes by highlighting important future directions, emphasizing the need for an integrated, collaborative, cross-species, and multilevel approach to tackling anhedonic phenotypes.
引用
- Pizzagalli DA. Toward a Better Understanding of the Mechanisms and Pathophysiology of Anhedonia: Are We Ready for Translation? Am J Psychiatry. 2022. PMID: 35775159. doi:10.1176/appi.ajp.20220423
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。